Published in Immunobiology on June 11, 2010
Synergistic effect of methionine encephalin (MENK) combined with pidotimod(PTD) on the maturation of murine dendritic cells (DCs). Hum Vaccin Immunother (2013) 0.78
Methionine enkephalin (MENK) improves lymphocyte subpopulations in human peripheral blood of 50 cancer patients by inhibiting regulatory T cells (Tregs). Hum Vaccin Immunother (2014) 0.77
Lipid-Conjugation of Endogenous Neuropeptides: Improved Biotherapy against Human Pancreatic Cancer. Adv Healthc Mater (2015) 0.77
Endogenous opioid inhibition of proliferation of T and B cell subpopulations in response to immunization for experimental autoimmune encephalomyelitis. BMC Immunol (2015) 0.76
Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis. Exp Biol Med (Maywood) (2015) 0.75
Herpes simplex virus-specific memory CD8+ T cells are selectively activated and retained in latently infected sensory ganglia. Immunity (2003) 4.49
The biology of the opioid growth factor receptor (OGFr). Brain Res Brain Res Rev (2002) 1.71
Stress-induced elevation of glucocorticoids increases microglia proliferation through NMDA receptor activation. J Neuroimmunol (2005) 1.66
Psychological stress compromises CD8+ T cell control of latent herpes simplex virus type 1 infections. J Immunol (2007) 1.65
Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin. Exp Biol Med (Maywood) (2011) 1.47
Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model. Exp Biol Med (Maywood) (2011) 1.44
In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer. Front Oncol (2012) 1.43
Prenatal transfer of low amounts of herpes simplex virus (HSV)-specific antibody protects newborn mice against HSV infection during acute maternal stress. Brain Behav Immun (2004) 1.42
Under-expression of the opioid growth factor receptor promotes progression of human ovarian cancer. Exp Biol Med (Maywood) (2012) 1.39
Regulation of cell proliferation by the opioid growth factor receptor is dependent on karyopherin beta and Ran for nucleocytoplasmic trafficking. Exp Biol Med (Maywood) (2010) 1.38
The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation. Mol Biol Cell (2008) 1.25
Naltrexone, an opioid antagonist, facilitates reepithelialization of the cornea in diabetic rat. Diabetes (2002) 1.10
Estrogen stimulates microglia and brain recovery from hypoxia-ischemia in normoglycemic but not diabetic female mice. J Clin Invest (2004) 1.04
Modulation of microglia and CD8(+) T cell activation during the development of stress-induced herpes simplex virus type-1 encephalitis. Brain Behav Immun (2007) 1.03
Use of topical insulin to normalize corneal epithelial healing in diabetes mellitus. Arch Ophthalmol (2007) 1.01
Regulation of natural killer T-cell development by deubiquitinase CYLD. EMBO J (2010) 1.01
The dual role of CD8+ T lymphocytes in the development of stress-induced herpes simplex encephalitis. J Neuroimmunol (2003) 0.98
Opioid growth factor-opioid growth factor receptor axis is a physiological determinant of cell proliferation in diverse human cancers. Am J Physiol Regul Integr Comp Physiol (2009) 0.98
Opioid growth factor suppresses expression of experimental autoimmune encephalomyelitis. Brain Res (2009) 0.97
The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer. Cancer Res (2007) 0.96
Corticosterone impairs dendritic cell maturation and function. Immunology (2007) 0.95
Topically applied naltrexone restores corneal reepithelialization in diabetic rats. J Ocul Pharmacol Ther (2007) 0.95
Stress-induced glucocorticoids at the earliest stages of herpes simplex virus-1 infection suppress subsequent antiviral immunity, implicating impaired dendritic cell function. J Immunol (2010) 0.94
Insulin treatment ameliorates impaired corneal reepithelialization in diabetic rats. Diabetes (2006) 0.94
Opioids and the apoptotic pathway in human cancer cells. Neuropeptides (2003) 0.93
Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function. Exp Biol Med (Maywood) (2008) 0.93
Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma. Cancer Chemother Pharmacol (2005) 0.93
The effects of stress on memory cytotoxic T lymphocyte-mediated protection against herpes simplex virus infection at mucosal sites. Brain Behav Immun (2002) 0.92
Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis. Am J Physiol Regul Integr Comp Physiol (2009) 0.92
Psychological stress impairs the local CD8+ T cell response to mucosal HSV-1 infection and allows for increased pathogenicity via a glucocorticoid receptor-mediated mechanism. Psychoneuroendocrinology (2008) 0.91
Immunoelectron microscopic localization of the opioid growth factor receptor (OGFr) and OGF in the cornea. Brain Res (2003) 0.91
Nucleocytoplasmic distribution of opioid growth factor and its receptor in tongue epithelium. Anat Rec A Discov Mol Cell Evol Biol (2005) 0.91
Treatment of advanced pancreatic cancer with opioid growth factor: phase I. Anticancer Drugs (2004) 0.90
Opioids and differentiation in human cancer cells. Neuropeptides (2005) 0.90
The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer. Mol Cancer (2008) 0.89
Naltrexone accelerates healing without compromise of adhesion complexes in normal and diabetic corneal epithelium. Brain Res Bull (2007) 0.89
Dry eye reversal and corneal sensation restoration with topical naltrexone in diabetes mellitus. Arch Ophthalmol (2009) 0.88
Differential effects of vascular growth factors on arterial and venous angiogenesis. J Vasc Surg (2002) 0.88
A novel inhibitor of inflammatory cytokine production (CNI-1493) reduces rodent post-hemorrhagic vasospasm. Neurocrit Care (2006) 0.88
Corticosterone impairs MHC class I antigen presentation by dendritic cells via reduction of peptide generation. J Neuroimmunol (2004) 0.88
Naltrexone and insulin are independently effective but not additive in accelerating corneal epithelial healing in type I diabetic rats. Exp Eye Res (2009) 0.87
Psychological stress exacerbates primary vaginal herpes simplex virus type 1 (HSV-1) infection by impairing both innate and adaptive immune responses. Brain Behav Immun (2008) 0.87
Dependence on nuclear localization signals of the opioid growth factor receptor in the regulation of cell proliferation. Exp Biol Med (Maywood) (2009) 0.86
Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy. J Immunol (2014) 0.85
Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis. BMC Cancer (2009) 0.85
Topical application of naltrexone facilitates reepithelialization of the cornea in diabetic rabbits. Brain Res Bull (2009) 0.85
Capsaicin-mediated denervation of sensory neurons promotes mammary tumor metastasis to lung and heart. Anticancer Res (2004) 0.85
Prevention and delay in progression of human pancreatic cancer by stable overexpression of the opioid growth factor receptor. Int J Oncol (2008) 0.84
Opioids and migration, chemotaxis, invasion, and adhesion of human cancer cells. Neuropeptides (2007) 0.84
Stress presents a problem for dendritic cells: corticosterone and the fate of MHC class I antigen processing and presentation. Brain Behav Immun (2006) 0.84
Corneal safety of topically applied naltrexone. J Ocul Pharmacol Ther (2006) 0.84
Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck. Cancer Chemother Pharmacol (2005) 0.83
Particle-mediated gene transfer of opioid growth factor receptor cDNA regulates cell proliferation of the corneal epithelium. Cornea (2005) 0.83
Opioid growth factor arrests the progression of clinical disease and spinal cord pathology in established experimental autoimmune encephalomyelitis. Brain Res (2012) 0.83
Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells. Int J Oncol (2007) 0.83
The opioid growth factor-opioid growth factor receptor axis regulates cell proliferation of human hepatocellular cancer. Am J Physiol Regul Integr Comp Physiol (2009) 0.82
The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice. Gynecol Oncol (2011) 0.82
Passive diffusion of naltrexone into human and animal cells and upregulation of cell proliferation. Am J Physiol Regul Integr Comp Physiol (2009) 0.82
Adaptation of homeostatic ocular surface epithelium to chronic treatment with the opioid antagonist naltrexone. Cornea (2006) 0.82
Opioid growth factor (OGF) inhibits anchorage-independent growth in human cancer cells. Int J Oncol (2004) 0.82
Neutralizing antibody against interleukin-6 attenuates posthemorrhagic vasospasm in the rat femoral artery model. Neurosurgery (2004) 0.81
The expression and function of the OGF-OGFr axis - a tonically active negative regulator of growth - in COS cells. Neuropeptides (2003) 0.81
Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis. Exp Biol Med (Maywood) (2009) 0.81
Opioid growth factor - opioid growth factor receptor axis inhibits proliferation of triple negative breast cancer. Exp Biol Med (Maywood) (2013) 0.80
Regulation of corneal repair by particle-mediated gene transfer of opioid growth factor receptor complementary DNA. Arch Ophthalmol (2006) 0.80
T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases. Immunobiology (2010) 0.80
Regulation of Tenon's capsule fibroblast cell proliferation by the opioid growth factor and the opioid growth factor receptor axis. Invest Ophthalmol Vis Sci (2010) 0.80
Postpartum maternal corticosterone decreases maternal and neonatal antibody levels and increases the susceptibility of newborn mice to herpes simplex virus-associated mortality. J Neuroimmunol (2004) 0.80
Treatment of a relapse-remitting model of multiple sclerosis with opioid growth factor. Brain Res Bull (2013) 0.79
Topical treatment with the opioid antagonist naltrexone accelerates the remodeling phase of full-thickness wound healing in type 1 diabetic rats. Exp Biol Med (Maywood) (2013) 0.79
Targeting opioidergic pathways as a novel biological treatment for advanced pancreatic cancer. Expert Rev Gastroenterol Hepatol (2012) 0.79
Ocular surface abnormalities related to type 2 diabetes are reversed by the opioid antagonist naltrexone. Clin Experiment Ophthalmol (2013) 0.79
Expression of opioid growth factor (OGF)-OGF receptor (OGFr) axis in human nonmedullary thyroid cancer. Thyroid (2008) 0.79
Opioid growth factor receptor is unaltered with the progression of human pancreatic and colon cancers. Int J Oncol (2006) 0.79
Opioid growth factor inhibits intimal hyperplasia in balloon-injured rat carotid artery. J Vasc Surg (2003) 0.79
A marked reduction in priming of cytotoxic CD8+ T cells mediated by stress-induced glucocorticoids involves multiple deficiencies in cross-presentation by dendritic cells. J Immunol (2010) 0.79
Opioid growth factor modulation of corneal epithelium: uppers and downers. Curr Eye Res (2003) 0.78
Prevention of exuberant granulation tissue and neovascularization in the rat cornea by naltrexone. Arch Ophthalmol (2008) 0.78
Elevated maternal corticosterone during lactation hinders the neonatal adaptive immune response to herpes simplex virus (HSV) infection. Brain Behav Immun (2007) 0.78
Transplacental transfer and subsequent neonate utilization of herpes simplex virus-specific immunity are resilient to acute maternal stress. J Virol (2003) 0.78
Impact of maternal stress on the transmammary transfer and protective capacity of herpes simplex virus-specific immunity. Am J Physiol Regul Integr Comp Physiol (2004) 0.78
Opioid growth factor (OGF) for hepatoblastoma: a novel non-toxic treatment. Invest New Drugs (2012) 0.77
The effect of Helicobacter hepaticus infection on immune responses specific to herpes simplex virus type 1 and characteristics of dendritic cells. Comp Med (2009) 0.77
Gene expression of OGFr in the developing and adult rat brain and cerebellum. Brain Res Bull (2004) 0.77
Internalization of the opioid growth factor, [Met5]-enkephalin, is dependent on clathrin-mediated endocytosis for downregulation of cell proliferation. Am J Physiol Regul Integr Comp Physiol (2010) 0.77
Low Dose Naltrexone for Treatment of Multiple Sclerosis: A Retrospective Chart Review of Safety and Tolerability. J Clin Psychopharmacol (2015) 0.77
Astrocyte proliferation is regulated by the OGF-OGFr axis in vitro and in experimental autoimmune encephalomyelitis. Brain Res Bull (2012) 0.77
Expression of the opioid growth factor-opioid growth factor receptor axis in human ovarian cancer. Gynecol Oncol (2011) 0.76
Spontaneous episodic decreased tear secretion in rats is related to opioidergic signaling pathways. Invest Ophthalmol Vis Sci (2012) 0.76
Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer. Exp Biol Med (Maywood) (2013) 0.76
Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets. Int J Cancer (2014) 0.75